Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 7/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | DHCR24 | Q15392 | 3/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102184 | 1.00 | CHRM2 (0.34) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL5095308 | 0.85 | USP2 (0.38) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL5095310 | 0.85 | USP2 (0.38) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL25069171 | 0.82 | BRD4 (0.38) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL6180497 | 0.81 | GRM1 (0.32) | — | |
| SCHEMBL22866385 | 0.78 | ALDH1A1 (0.37) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL22532271 | 0.77 | INPP5A (0.33) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL7334201 | 0.77 | CHRM2 (0.44) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL1154488 | 0.74 | USP2 (0.33) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL1154487 | 0.74 | USP2 (0.33) | CHRM2CHRM1CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449461-B2 | Benzathiazol-acetamides | HOFFMANN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1773795-A1 | SUBSTITUTED BENZOTHIAZOLES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-18 | — | — | EP | disclosed |
| US-20060019950-A1 | Benzathiazol-acetamides | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-01-26 | — | — | US | disclosed |
| WO-2006008040-A1 | SUBSTITUTED BENZOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019950-A1 | Benzathiazol-acetamides | CHRNA2, CHRNA10, CHRNA5 | CHRM2 37/4885CHRM1 33/4885CHRM4 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.